Skip to main content
SpringerLink
Log in

Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — impact on the immune and other systems

  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Seremetis S, Aledort LM, Bona R et al. (1992) A three-year randomized prospective study of high or intermediate purity factor VIII concentrates in asymptomatic HIV+ hemophiliacs: effects on immune function. Blood 80 [Suppl 1]:366a

    Google Scholar 

  2. De Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA (1992) The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 78: 1919–1922

    Google Scholar 

  3. De Biasi R, Rocino A (1992) The impact of very-high-purity, monoclonally purified factor VIII concentrates on the immune system of HIV-positive hemophiliacs. World Federation of Hemophilia Congress Abstracts, p220

  4. Mannucci PM, Gringeri A, De Biasi R, Baudo F, Morfini M, Ciavarella N (1992) Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemost 67: 310–313

    PubMed  Google Scholar 

  5. Mannucci PM, Abildgaard CF, Aledort LM et al. (1992): Immunologic studies in HIV-positive and HIV-negative hemophiliacs receiving recombinant factor VIII (Kogenate) — a 3-year update. Blood 80 [Suppl 1]:230a

    Google Scholar 

  6. Gomperts ED, De Biasi R, De Vreker R (1992) The impact of clotting factor concentrates on the immune system in individuals with hemophilia. Transfu Med Rev 4:44–54

    Google Scholar 

  7. Beddal AC, Hill FGH, George RH, Williams MD, Al-Rubei K (1985) Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital. J Clin Pathol 38:1163–1165

    PubMed  Google Scholar 

  8. Brettler DB, Forsberg AD, Brewster F, Sullivan JL, Levine PH (1986) Delayed cutaneous hypersensitivity reactions in hemophiliac subjects treated with factor concentrates. Am J Hematol 81:607–611

    Google Scholar 

  9. Lederman MM, Saunders C, Toossi Z, Lemon N, Barbara E, Ratnoff OD (1986) Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 107:477–478

    Google Scholar 

  10. Matheson DS, Green BJ, Poon M-C, Bowen TJ, Fritzler MJ, Hoar DI (1986) T-lymphocytes from hemophiliacs proliferate after exposure to factor VIII product. Vox Sang 51:92–95

    PubMed  Google Scholar 

  11. Matheson DS, Green BJ, Fritzler MJ, Poon M-C, Bowen TJ, Hoar DI (1987) Humoral immune response in patients with hemophilia. Clin Immunol Immunopathol 44:41–50

    PubMed  Google Scholar 

  12. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW (1989) Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 71:387–391

    PubMed  Google Scholar 

  13. Madhok R, Gracie JA, Smith J, Lowe GDO, Forbes CD (1990) Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV-1 infection. Br J Haematol 76: 70–74

    PubMed  Google Scholar 

  14. Matheson DS, Green GJ, Poon M-C, Fritzler MJ, Hoar DI, Bowen TJ (1986) Natural killer cell activity from hemophiliacs exhibits differential responses to various forms of interferon. Blood 67:164–167

    PubMed  Google Scholar 

  15. Pasi KJ, Hill FGH (1990) In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity. Br J Haematol 76:88–93

    PubMed  Google Scholar 

  16. Eibl MM, Ahmad R, Wolf HM, Linnau Y, Götz E, Mannhalter JW (1987) A component of factor VIII preparations which can be separated from factor VIII activity down-modulates human monocyte functions. Blood 69:1153–1160

    PubMed  Google Scholar 

  17. Mannhalter JW, Ahman R, Leibl H, Göttlicher J, Wolf HM, Eibl MM (1988) Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity. Br J Haematol 71:1662–1668

    Google Scholar 

  18. Mannhalter JW, Ahman R, Eibl MD, Leibl H (1990) Modulation of human monocyte functions by factor VIII-anti factor VIII complexes present in an affinity-purified factor VIII product. Blood 75:810–811

    Google Scholar 

  19. Baxter Healthcare Corporation (1992) Hyland Division: Antihemophilic factor (recombinant) Recombinate. Product Insert

  20. Gomperts E, Lundblad R, Adamson R (1992) The manufacturing process for recombinant factor VIII, Recombinate. Transfus Med Rev 6:247–251

    PubMed  Google Scholar 

  21. Prentice CRM, Izzat MM, Adams JF, McNicol GP, Douglas AS (1971) Amyloidosis associated with the nephrotic syndrome and transfusion reactions in haemophilia. Br J Haematol 21:305–311

    PubMed  Google Scholar 

  22. Goldsmith GH, Baily RG, Brettler DB et al. (1988) Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med 108:797–799

    PubMed  Google Scholar 

  23. Eyster ME, Nau ME (1978) Particulate material in antihemophilic factor (AHF) concentrates. Transfusion 18:567–581

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pediatrics, University of Calgary, Foothills Hospital, 1403-29th Street N.W., Calgary, Alberta, Canada

    M. -C. Poon

Authors
  1. M. -C. Poon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poon, M.C. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — impact on the immune and other systems. Ann Hematol 68 (Suppl 3), S83–S86 (1994). https://doi.org/10.1007/BF01774544

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01774544

Keywords

Search

Navigation